Entelexo Biotherapeutics
YC W21Irvine, US · Founded 2020 · 3 employees · 2 known investors
Entelexo develops engineered exosome therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company uses a proprietary platform to design exosomes that communicate with multiple diseased cell types simultaneously, replacing traditional single-target treatments.
Also known as Entelexo · Entelexo, Inc.
Founders & leadership· Y Combinator alumni (W21)
Entelexo Biotherapeutics was founded in 2020 by MILAD RIAZIFAR, Todd Schurr, and Cameron Taylor.
Investors · 2
Company profile
researched Aug 2026Entelexo Biotherapeutics is a preclinical-stage biotechnology company developing a new class of exosome-based therapeutics for autoimmune diseases. Exosomes are described by the company as the body's natural cell-to-cell communication system, delivering messages that cells interpret through surface receptors. Entelexo has built a rational engineering platform intended to use this communication network by engineering exosomes that deliver messages to multiple, specific cell types at the same time.
The company targets autoimmune indications including rheumatoid arthritis, Crohn's disease, and psoriasis, arguing that existing therapies are formulated as one-size-fits-all agents that block a single cytokine such as TNF-alpha and therefore do not address diseases involving several cell types and pathways. Its stated approach combines patient-focused analysis of disease patterns and use of data to optimize product efficacy, with a platform meant to rapidly create and fine-tune indication-specific exosome treatments.
Entelexo reports an initial pipeline of products whose drug candidates have been de-risked using human cell assays. Per its published timeline, drug candidate development was completed and lead candidates selected in 2022, with IND-enabling animal studies beginning and Pre-IND filing preparations with the FDA underway in 2023.
Traction
The company's published timeline reports: 2020 founding, an operational lab, filing of multiple patents, and Y Combinator acceptance; 2021 Y Combinator graduation, completion of a pre-seed raise, formation of a Scientific Advisory Board, EFL acceptance, and candidate development and proof-of-concept testing; 2022 staging of pre-IND animal studies, EFL graduation, start of patent prosecution, winning the Pitch.Launch.Grow. Biotech Competition, completion of drug candidate development, efficacy evaluation by human cell immunoassays, and selection of lead drug candidates; and 2023 presentation at a J.P. Morgan biotech showcase, commencement of IND-enabling animal studies, and preparations to file for Pre-IND with the FDA.
Latest developments
As of the most recent company timeline entries for 2023, Entelexo was presenting at a J.P. Morgan biotech showcase, had begun IND-enabling animal studies, and was preparing to file for Pre-IND with the FDA.
▸Full profile — market position, technology, go-to-market, history
Market position
Entelexo positions itself against existing autoimmune therapies that it characterizes as one-size-fits-all agents blocking a single cytokine such as TNF-alpha, proposing multi-cell-type exosome signaling as an approach better matched to the complexity of these diseases.
Differentiation is claimed on the basis of engineered exosomes that address multiple specific diseased cell types at once, in contrast to single-cytokine blockade, together with an engineering platform that supports rapid prototyping and creation of indication-specific candidates and an initial pipeline de-risked through human cell assays.
Technology
The core technology is a proprietary rational engineering platform for exosomes, the vesicles the company describes as nature's cell-to-cell communication system that deliver messages recognized via receptors on recipient cell surfaces. Entelexo engineers exosomes to communicate with multiple, specific types of diseased cells simultaneously, rather than blocking a single cytokine target, and states the platform allows rapid prototyping and fine-tuning of indication-specific exosome therapeutics. Candidate efficacy has been assessed using human cell assays and human cell immunoassays.
Go-to-market
The company addresses patients with autoimmune diseases, specifically citing rheumatoid arthritis, Crohn's disease, and psoriasis, which it describes as affecting millions of patients with no cure.
History
Entelexo was founded in 2020, establishing a laboratory and filing multiple patent applications in its first year, and was accepted into Y Combinator. It graduated from Y Combinator in 2021, completed a pre-seed raise, formed a Scientific Advisory Board, and joined the EFL program, while conducting candidate development and proof-of-concept testing. In 2022 it graduated from EFL, began patent prosecution, completed drug candidate development, evaluated efficacy through human cell immunoassays, selected lead drug candidates, staged pre-IND animal studies, and won the Pitch.Launch.Grow. Biotech Competition. In 2023 it began IND-enabling animal studies and preparations for a Pre-IND filing with the FDA.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Entelexo Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 8
launches, deals, and filingsThe company reported starting IND-enabling animal studies and beginning preparations to file for Pre-IND with the FDA.
Drug candidate development was completed, efficacy was evaluated using human cell immunoassays, lead candidates were selected, pre-IND animal studies were staged, patent prosecution started, and the company graduated from EFL.
Company timeline lists completion of a pre-seed raise in 2021; no amount or investors disclosed.
The company graduated from Y Combinator, formed a Scientific Advisory Board, and was accepted into EFL in 2021.
Company timeline records YC acceptance in 2020, followed by YC graduation in 2021.
In its founding year the company reported making its laboratory operational and filing multiple patent applications.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Entelexo Biotherapeuticsentelexo.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Entelexo Biotherapeutics do?
- Preclinical biotech engineering exosome therapeutics that signal to multiple diseased cell types for autoimmune diseases.
- Who founded Entelexo Biotherapeutics?
- Entelexo Biotherapeutics was founded by MILAD RIAZIFAR, Todd Schurr, Cameron Taylor in 2020.
- Who are Entelexo Biotherapeutics's investors?
- Entelexo Biotherapeutics's investors include Founders, Y Combinator.
- Where is Entelexo Biotherapeutics headquartered?
- Entelexo Biotherapeutics is headquartered in Irvine, US.